<DOC>
	<DOCNO>NCT00705614</DOCNO>
	<brief_summary>Prospective , observational , parallel-group , postmarketing safety surveillance registry participant treat Remicade standard therapy active fistulizing Crohn 's disease ( CD ) . The follow-up period 5 year . The participant standard therapy group may switch Remicade time follow-up period</brief_summary>
	<brief_title>Postmarketing Safety Surveillance European Registry Crohn 's Disease Patients Treated With Remicade Standard Therapy ( MK-2155-035 )</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>At least 18 year age , either sex , race . Must active fistulizing CD must experience least 1 follow : fail taper regimen corticosteroid initiate immunosuppressive therapy require corticosteroid treatment previous 6 month initiate immunosuppressive therapy luminal fistulizing CD , , treat physician 's judgment , qualifies initiation Remicade . Willing give write informed consent must able adhere procedural requirement registry . Must evaluate active inactive ( latent ) tuberculosis ( TB ) Baseline Visit . TB evaluation consist TB history question ( eg , medical history , possible previous contact TB , TB vaccination history ) . TB evaluation TB screening ( eg , skin test , chest xray ) require subject start treatment Remicade . In case , subject must screen TB within 3 month prior initiate Remicade treatment . Female pregnant nursing . Treated Remicade prior Baseline . Previously treat tumor necrosis factor ( TNF ) active agent investigational drug CD prior Baseline . Active untreated latent TB severe infection sepsis , abscess , opportunistic infection . Moderate severe heart failure ( New York Heart Association [ NYHA ] Class III : subject mark limitation activity ; comfortable rest/Class IV : subject complete rest , confine bed chair ; physical activity bring discomfort symptom occur rest ) . Have lymphoproliferative disorder ( eg , lymphoma ) malignancy . In situation condition , opinion treat physician , may interfere optimal participation registry . Are participate clinical trial ( exclude registry ) . In addition , subject exclude treatment Remicade criterion list meet : Females childbearing potential unwilling use medically accept method birth control treatment Remicade continue use least 6 month last Remicade treatment . History hypersensitivity murine proteins excipients Remicade formulation ( sucrose , polysorbate 80 , monobasic sodium phosphate , dibasic sodium phosphate ) . Other condition contraindicate Remicade Summary Product Characteristics ( SPC ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>